Sort
48,018 grants matching “immunotherapy”
Phenotypic, Functional and Transcriptional Heterogeneity in T Cell Exhaustion
$400,000Weiguo Cui · Northwestern University At Chicago · R01 · FY2023 · AI
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
$400,000George Coukos · University Of Pennsylvania · R01 · FY2012 · FD
OSTEOGENIC AND IMMUNOMODULATORY PROPERTIES OF DECIDUOUS TOOTH STEM CELLS
$400,000Songtao Shi · University Of Pennsylvania · R01 · FY2015 · DE
Immunopathogenesis of Toxoplasmic encephalitis
$400,000Christopher A Hunter · University Of Pennsylvania · R01 · FY2016 · AI
Comprehensive Cancer Center Program at Fox Chase
$400,000Jonathan D. Chernoff · Research Inst Of Fox Chase Can Ctr · P30 · FY2022 · CA
Development of a novel, RNA-interference-based therapeutic to treat prostate cancer
$400,000Robert Schickel · Nuago Therapeutics Inc · R41 · FY2024 · CA
Enzymology of Mismatch Repair in Yeast
$400,000Richard D Kolodner · Ludwig Institute For Cancer Res Ltd · R01 · FY2022 · GM
A parallelized computational microscope platform for high-throughput live imaging of patient-derived organoids
$400,000Mark Harfouche · Ramona Optics, Inc. · R44 · FY2024 · CA
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · AI
The Immunosuppressive Function of Checkpoint Kinase 2 in Gliomas
$400,000Crismita Clement Dmello · Northwestern University At Chicago · R01 · FY2025 · NS
SBIR Phase II: Clinical-Scale Suspension Bioreactor for Primary Hematopoietic Culture
$400,000Todd A McAdams · Tissue Therapeutics · · FY2000 · TIP
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$400,000Jeffrey A Sosman · Vanderbilt University · R01 · FY2013 · FD
Signaling functions of Peli family of E3 ubiquitin ligases
$400,000Shao-Cong Sun · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · AI
Point-of-care autologous CAR-T cell manufacturing
$400,000Yu-Tsueng Liu · Aerocytek, Inc. · R43 · FY2025 · CA
SBIR PHASE I - TOPIC 405 - PROJECT TITLE: IN VIVO PHARMACOTYPING OF COMBINATION THERAPY IN PRIMARY BRAIN TUMORSFIRM FIXED PRICE - POP: 09/16/2020 - 0
$400,000Christian Knoopke · Lodestone Biomedical, Llc · N43 · FY2020 · CA
OSTEOGENIC AND IMMUNOMODULATORY PROPERTIES OF DECIDUOUS TOOTH STEM CELLS
$400,000Songtao Shi · University Of Pennsylvania · R01 · FY2016 · DE
IL-27 and Treg cells
$400,000Christopher A Hunter · University Of Pennsylvania · R01 · FY2015 · AI
Fourth-Generation Nanopore-Assisted Sequencing for Advanced Oncological Analyses
$400,000Eric Mayo Peterson · Electronic Biosciences, Inc. · R43 · FY2024 · CA
Protective and Pathologic Roles for CD8+ T cells in Leishmaniasis
$400,000Phillip A. Scott · University Of Pennsylvania · R01 · FY2014 · AI
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$399,999Jeffrey A Sosman · Vanderbilt University · R01 · FY2010 · FD
Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs
$399,999Scott D Eliasof · Culnexin Therapeutics, Inc. · R41 · FY2021 · CA
CANCER CENTER SUPPORT GRANT
$399,999University Of Colorado Denver · P30 · FY2002 · CA
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
$399,999Mallikarjun Srivatsan · Accurius Therapeutics, Inc. · R44 · FY2023 · CA
Mechanisms of Immune Cell Response to Mechanical Load
$399,998Arpita Upadhyaya · University Of Maryland, College Park · · FY2016 · ENG
FY20 SBIR PHASE I TOPIC #400 - AMBAY RADI-SENSE: NON-INVASIVE, NOVEL TEST TO MONITOR BIOLOGICAL RESPONSE TO RADIOTHERAPY
$399,997Meena Chandok · Ambay Immune Sensors And Controls, Llc · N43 · FY2020 · CA